North American Neuro Ophthalmology Society (NANOS)

04/14/2026

A large FDA adverse event analysis shows that , especially the higher-dose weight-loss formulation Wegovy, is strongly associated with , with a significantly higher risk in men, suggesting a potential dose-dependent safety signal requiring urgent prospective evaluation.

https://bjo.bmj.com/content/early/2026/03/02/bjo-2025-328483

04/09/2026

Meta-analysis finds no consistent, statistically significant increase in NAION risk with semaglutide overall, though evidence is low-certainty due to high heterogeneity and confounding, with possible variation by indication.

Read more: https://pubmed.ncbi.nlm.nih.gov/41692115

03/20/2026

Let’s talk safety. Visit ENSPRYNG at booth #2 during NANOS 2026. Read Important Safety Information
at bit.ly/4oXEbzz and Prescribing Information at bit.ly/ENSPRYPI.

ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. It is not known if ENSPRYNG is safe and effective in children.

ENSPRYNG is a subcutaneous injection given every 4 weeks after taking 3 starting doses in the first month. After doctor approval and training, ENSPRYNG can be self-administered. Before and during treatment, your doctor may order tests and monitor you to ensure ENSPRYNG is still right for you.

If a starting dose is missed, take it immediately, and maintain the 2-week dosing interval from your new starting date until the first 3 doses are complete, then start ongoing doses every 4 weeks.

If an ongoing dose is missed, take it immediately, wait the 4-week interval from your new starting date, then continue with doses every 4 weeks. Talk to your doctor if you have questions on restarting treatment or if it’s been more than 8 weeks since your last dose.

ENSPRYNG, if unopened, can be removed from and returned to refrigeration. The total combined time out of refrigeration shouldn’t exceed 8 days above 86°F.

ENSPRYNG may cause serious side effects including: infections, increased liver enzymes, and low neutrophil counts. All required vaccinations should be completed before starting ENSPRYNG. Do not take ENSPRYNG if you are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG, have an active hepatitis B infection, or have active or untreated inactive (latent) TB.

These are not all the possible side effects of ENSPRYNG. Call your doctor for medical advice about side effects.

02/17/2026

The THEIA phase 3 trial compared intravenous alteplase versus aspirin within 4.5 hours in acute and found no significant visual benefit with alteplase, though it appeared safe; the study was underpowered, and further research is needed. Read here: https://loom.ly/H7VXM_c

02/10/2026

The QRK207 trial investigated progression in 599 eyes with acute NAION. Visual worsening was common early after onset, mostly within 22 days. Cardiovascular risk factors were not associated with progression. The only consistent significant risk factor for both visual acuity and visual field deterioration was a history of NAION in the fellow eye. Read here: https://loom.ly/aGCX-aA

11/28/2025

The countdown begins . . .
NANOS 2026 is your chance to reconnect, reignite, and reimagine the future of neuro-ophthalmology.
Boston, March 20–24, 2026.
Register early, book your hotel, RSVP View Boston.
nanosweb.org/nanos2026

11/24/2025

What does it look like to go blind? This artist with diabetic eye disease tried to capture his experience: https://ow.ly/sRNZ50XevNT

Mark Rouse created a series of four paintings, each depicting the same mountain range, but at different points in Mark’s recovery, beginning when he was legally blind through the restoration of his si

11/17/2025

Children can get diabetic retinopathy, too. Read more here: https://ow.ly/g78650XevME

Children diagnosed with type 2 diabetes are nearly twice as likely than those with type 1 diabetes to develop diabetic retinopathy within 15 years of their diagnosis, a study finds.

11/14/2025

Early-Bird Registration is officially open.
NANOS 2026 is coming to Boston, March 20–24.
Register early, book your hotel, RSVP View Boston.
Secure your spot before rates go up.
nanosweb.org/nanos2026

11/10/2025

Managing diabetes can be overwhelming. See tips from ophthalmologists: https://ow.ly/ATRf50XevKF

Constant attention to diet and blood sugar can leave patients with diabetes feeling overwhelmed. Find out what to do if you have diabetes distress or diabetes burnout.

11/03/2025

Diabetes is a leading cause of blindness. Learn more here: https://ow.ly/MQbY50XevNB

Diabetic eye disease is a term for several eye problems that can all result from diabetes, including diabetic retinopathy, diabetic macular edema, cataract and glaucoma.

10/30/2025

The NANOS October Spotlight is now available! You can read it here: https://loom.ly/nntrgWg